Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), ... vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias progression or deaths (PFS)detailed results ASP8273, 2019 1.61 [1.09; 2.39]
1.61 [1.09 ; 2.39 ] ASP8273, 2019 1 0% 530 NA not evaluable DCRdetailed results ASP8273, 2019 0.84 [0.59; 1.20]
0.84 [0.59 ; 1.20 ] ASP8273, 2019 1 0% 530 NA not evaluable DORdetailed results ASP8273, 2019 0.94 [0.47; 1.90]
0.94 [0.47 ; 1.90 ] ASP8273, 2019 1 0% 214 NA not evaluable objective responses (ORR)detailed results ASP8273, 2019 0.53 [0.38; 0.76]
0.53 [0.38 ; 0.76 ] ASP8273, 2019 1 0% 530 NA not evaluable AE leading to death (grade 5)detailed results ASP8273, 2019 1.12 [0.68; 1.83]
1.12 [0.68 ; 1.83 ] ASP8273, 2019 1 0% 527 NA not evaluable SAE (any grade)detailed results ASP8273, 2019 1.35 [0.92; 1.97]
1.35 [0.92 ; 1.97 ] ASP8273, 2019 1 0% 527 NA not evaluable STRAE (any grade)detailed results ASP8273, 2019 2.85 [1.60; 5.06]
2.85 [1.60 ; 5.06 ] ASP8273, 2019 1 0% 527 NA not evaluable TRAE (any grade)detailed results ASP8273, 2019 0.51 [0.27; 0.96]
0.51 [0.27 ; 0.96 ] ASP8273, 2019 1 0% 527 NA not evaluable TRAE leading to death (grade 5)detailed results ASP8273, 2019 0.99 [0.06; 15.89]
0.99 [0.06 ; 15.89 ] ASP8273, 2019 1 0% 527 NA not evaluable TRAE leading to discontinuation (any grade)detailed results ASP8273, 2019 1.63 [0.87; 3.08]
1.63 [0.87 ; 3.08 ] ASP8273, 2019 1 0% 527 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-02 17:07 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220
- treatments: 914